Decreased expression of DAB2IP is often detected in aggressive prostate cancer cells, and this loss of DAB2IP is primarily due to altered epigenetic regulation of its promoter particularly by histone acetylation 17, 18. This evidence concerns the gene DAB2IP and prostate carcinoma.